2 dated items from 2025, newest first. Every entry carries the date of the development rather than the date we wrote it, and names its source.
Consolidation, and the evidence that reframed treatment as ongoing.
What 2025 changed for people paying for tirzepatide
The withdrawal evidence landed: participants moved to placebo regained substantially, while those continuing held or kept losing. That single result is why this site models cost over years rather than months. The head-to-head against semaglutide reported in the same period, giving the first randomised comparison between the two molecules.
Commercially, the compounded market began consolidating toward smaller operators while the large consumer platforms moved to brand-only models — a shift that raised the value of verifying who actually compounds your medicine.
How to read a dated archive
Anything in this category ages badly. Manufacturer pricing has moved more than once in a single year, regulatory positions have shifted between proposal and final rule, and programs have entered and left the compounded market inside a quarter. An item dated here was accurate on that date and may not be now.
Where a story is still moving we say so in the item rather than implying it is settled. If you find something here that has been overtaken, tell us through contact — corrections are logged with the date they were made, and an archive nobody corrects is just a record of what we used to believe.
| Date | Category | Story |
|---|---|---|
| 2025-12-04 | Clinical | SURMOUNT-5 puts tirzepatide 20.2% against semaglutide 13.7% |
| 2025-11-10 | Clinical | Withdrawal data reframe tirzepatide as maintenance therapy, not a course |
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.